US-based Oraya Therapeutics has secured CE Mark extension for its IRay Radiotherapy system to treat patients with choroidal metastases.
The new indication expands the company's previous approval of the system to treat wet age related macular degeneration (AMD).
Choroidal metastases is a cancer in the eye that develops most commonly from primary sites in the breast or lung. Unlike ocular melanomas, choroidal metastases can grow quickly and needs prompt treatment to prevent vision loss.
Approval allows the company to offer a new treatment option for a vision-threatening condition for patients in the UK, Germany and Switzerland.
Oraya CEO Jim Taylor said: "This oncology indication demonstrates the breadth of possibilities that are enabled by the proprietary aspects of the IRay platform.
"While Oraya's primary focus remains on treating wet AMD, we continue to identify and evaluate other uses of the technology that may benefit patients and clinicians."
Radiation therapy is the preferred treatment using either plaque brachytherapy or external beam radiation therapy (EBRT), invasive procedures requiring therapy regimens conducted over days or weeks.
University of Essen head of the department for posterior segment diseases Norbert Bornfeld said: "The precision and simplicity enabled by the Oraya technology offer potential advantages compared to existing alternatives.
"There is real opportunity to evolve this technology further, providing a meaningful addition to our clinical treatments."
By using a robotically positioned low-energy X-ray source, the IRay Radiotherapy system delivers a precise dose of radiation to the back of the eye in a 15-20 minute non-invasive procedure.
The company said stereotactic radiation delivery and the use of low energy X-rays help to treat choroidal metastases without surgery and the related patient burden of multiple treatment sessions.
In March 2010, the IRay Radiotherapy system secured CE certification to treat wet AMD, and the company started actively commercialising Oraya Therapy in 2014.